# 2026-16837: FDA: ANDA or 505(b)(2)? Guidance helps drug makers pick paths.

2026-16837, Determining Whether To Submit an ANDA or a 505(b)(2) Application; Draft Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-08-18, effective Submit either electronic or written comments on the draft guidance by October 19, 2026 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. (as of 2026-08-25).

- Canonical: https://policyrisk.com/federal-register/2026-16837
- As of: 2026-08-25
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-16837
- Title: Determining Whether To Submit an ANDA or a 505(b)(2) Application; Draft Guidance for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 53418
- Published: 2026-08-18
- Effective: Submit either electronic or written comments on the draft guidance by October 19, 2026 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.
- Comments close: 2026-10-19
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-08-25

## In one line

FDA: ANDA or 505(b)(2)? Guidance helps drug makers pick paths.

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry titled "Determining Whether to Submit an ANDA or a 505(b)(2) Application." This draft guidance is intended to serve as a foundational guidance to assist applicants in determining which one of the abbreviated approval pathways under the Federal Food, Drug, and Cosmetic Act (FD&C Act) is appropriate for the submission of a marketing application to FDA. This draft guidance revises the guidance for industry titled "Determining Whether to Submit an ANDA or a 505(b)(2) Application" issued in May 2019 and, when finalized, will replace the 2019 guidance for industry.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-16837 on federalregister.gov](https://www.federalregister.gov/documents/2026/08/18/2026-16837/determining-whether-to-submit-an-anda-or-a-505b2-application-draft-guidance-for-industry)
- [2026-16837 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-08-18/pdf/2026-16837.pdf)

## Related
- [Previous: 2026-16836, Foreign-Trade Zone 16; Application for Subzone; Yazaki North America, Inc.; Pet…](https://policyrisk.com/federal-register/2026-16836)
- [Next: 2026-16838, Nominations to the Federal Insecticide, Fungicide, and Rodenticide Act Scientif…](https://policyrisk.com/federal-register/2026-16838)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-16837 (as of 2026-08-25).
